AGuIX nanoparticle (AGuIX)

AGuIX nanoparticle is a clinical-stage theranostic nanomedicine comprised of an ultrasmall (∼5 nm) polysiloxane matrix conjugated with multiple gadolinium chelates. Originally developed to act as both a magnetic resonance imaging (MRI) contrast agent and a radiosensitizer, AGuIX is designed to selectively accumulate in tumors through the enhanced permeability and retention (EPR) effect after intravenous injection[2][3][4][7]. The high local concentration of gadolinium enables both imaging enhancement and potentiation of radiotherapy by amplifying X-ray-induced damage in tumor cells; this occurs via emission of electrons and increased reactive oxygen species, which results in DNA damage and tumor cell death. AGuIX also serves as a versatile nanoplatform for incorporating various chelators or imaging/probe compounds (PET tracers, fluorophores)[2][5]. Preclinical evidence demonstrates rapid renal clearance and favorable safety profile, with ongoing clinical evaluation in solid tumor radiotherapy settings, particularly for brain metastases[4][7][9].

Other names

AGuIX®AGuIX nanoparticles

Radiosensitizer: enhances local radiation dose by emission of Auger electrons from gadolinium, increasing reactive oxygen species and DNA damage in tumor cells[3][7]; MRI contrast enhancement via gadolinium chelates[4][5][7]